Upgrade Overview

UBS has upgraded Swiss dental‑implant specialist Straumann (STMN.S) to a "Buy" rating, moving from a "Neutral" stance that had persisted for five years. The upgrade reflects UBS’s view that earnings momentum is improving and the valuation is attractive.

Valuation and Targets

The bank lifted its 12‑month price target to CHF 115.00, up from the prior target of CHF 90.00. This new target suggests an upside of approximately 23% relative to Straumann’s last closing price of CHF 93.20. UBS notes that Straumann currently trades at a 10% price‑to‑earnings premium to the European Healthcare index, well below its 10‑year average premium of 40%, indicating room for a material valuation re‑rating as earnings momentum strengthens.

Forecasts and Guidance

For the second half of 2026, UBS projects organic revenue growth of 10.3% and a core EBIT margin of 26.1%, both exceeding consensus expectations of 9.8% revenue growth and a 25.7% margin. Looking ahead to 2027, UBS models an additional 80 basis‑point expansion in core EBIT margin, surpassing the 30 basis‑point margin improvement implied by market consensus and exceeding Straumann’s own mid‑term framework target of 40‑50 basis points. The anticipated margin expansion is attributed to cost savings from the company’s Shanghai manufacturing facility and greater operational leverage.

Risks and Mitigants

UBS identifies the primary investor concerns—China’s Volume‑Based Procurement (VBP) policy, U.S. demand softness, and working‑capital requirements—as easing. The bank expects the upcoming second round of VBP to generate a modest 10%‑15% price reduction, which it believes will be largely offset by volume gains and market‑share expansion. Additionally, receivables growth that raised concerns in the first half of the year is considered exaggerated by seasonality and is expected to normalize, thereby supporting free‑cash‑flow conversion.

Market Position and Product Strength

Straumann is projected to continue outperforming the broader dental‑implant market, driven by market‑share gains from its iEXCEL product line. The combination of a favorable valuation relative to peers, improving earnings momentum, and strategic cost efficiencies underpins UBS’s upgraded stance.